Avalon GloboCare Corp.

DUBLIN, Sept. 26, 2023 /PRNewswire/ -- The "Mannequin-Based Simulation - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Mannequin-Based Simulation is experiencing significant growth, with an estimated value of US$1.2 billion in 2022. This market is projected to reach a substantial size of US$5.6 billion by 2030, reflecting a robust compound annual growth rate (CAGR) of 21% during the period from 2022 to 2030. Patient Simulators, a key segment within the Mannequin-Based Simulation market, are expected to grow at a CAGR of 20.4% and reach a market value of US$3.8 billion by the end of the analysis period. Additionally, the Other Product Types segment is estimated to experience even higher growth, with a projected CAGR of 22.4% over the next eight years. Regionally, the United States is a significant market, with an estimated value of US$530.1 million in 2022. China, the world's second-largest economy, is expected to see rapid growth, reaching a projected market size of US$347.4 million by 2030, with a remarkable CAGR of 26.5% during the forecast period. Other noteworthy geographic markets include Japan and Canada, both forecasted to grow at approximately 16.8% and 19.7% CAGR, respectively, from 2022 to 2030. Germany, within Europe, is also expected to achieve substantial growth, with a CAGR of approximately 19.7%. This comprehensive research report provides in-depth insights into the global Mannequin-Based Simulation market, focusing on patient simulators and other product types. It offers a detailed analysis of the competitive landscape, enabling businesses to formulate effective strategies for the future. Moreover, the report provides extensive coverage of geographic markets, including the United States, China, Japan, Canada, and Europe, highlighting their respective growth trajectories and opportunities. With access to digital archives, online collaborative updates, and complimentary updates for one year, this report is an invaluable resource for investors and businesses seeking to navigate and capitalize on the growth of the Mannequin-Based Simulation market in the coming years. Select Competitors (Total 55 Featured) Moog, Inc. Laerdal Medical AS Ambu A/S 3B Scientific GmbH Cardionics DentalEZ, Inc. Gaumard Scientific Co., Inc. IngMar Medical Kyoto Kagaku Co., Ltd. Mentice AB CAE Healthcare Adam Rouilly Ltd. Global Technologies KOKEN CO., LTD. LifeCast Body Simulation Ltd. These featured companies are significant players in the Mannequin-Based Simulation market, contributing to its growth and innovation. Please note that this list is not exhaustive, as the market includes numerous other players offering various products and services in this field. What`s New? Special discussions on the global economic climate and market sentiment Coverage on global competitiveness and key competitor percentage market shares Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to digital archives and trademarked research platform Complimentary updates for one year Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes Key Topics Covered: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS Increase in Surgeries Augurs Well for Market Growth Global Surgical Procedure Volume by Procedure Type Rise in Global Surgeries Post COVID & Shortage of Surgeons to Drive Use of Mannequin-based Simulation to Accelerate Surgeon Education and Training Surgical Backlog & Surgeon Shortages: A Harrowing Situation Cancer Surgery Demand Surges Amid Surgeon Shortage Mannequin-based Simulation to the Rescue As the Number of Surgeries Performed Globally Increase, the Need for Well Trained Surgeons Becomes Acute, Strengthening the Business Case for Mannequin-based Simulation: Global Market for General Surgery (In US$ Billion) for Years 2018, 2020, 2022, 2024, 2026 and 2028 Virtual Simulation and High-Fidelity Mannequin Simulation for Recognizing Critical Events High-fidelity Mannequins Advanced Mannequins Imitate Human Reactions Increasing Healthcare Expenditure to Foster Growth World Healthcare Expenditure (In US$ Trillion) for the Years for 2017, 2019, 2021, 2023 Mannequin-based Simulation for Nursing Schools Cardiology, a Promising Field for Medical Animation/Simulation Simulation Benefits Interventional Cardiology Mannequins Gain Traction in Military Medical Training Minimally-invasive Procedures Necessitate Simulation-based Training Robot-assisted Surgical Simulation Training Gaining Significance Simulation Training Preferred for Cataract Surgery Surgical Simulation Gets Notable Makeover with Influx of Innovative Approaches Surgical Simulation: The History & Evolution Existing Surgical Simulation Models Continuing Advances Pave Way for Versatile & Realistic Surgical Simulators Innovations Set to Take Surgical Simulation to Next Level Select Innovations Learning Theories Guiding Development of Simulation-based Education Areas where Under Graduate Nursing Education Simulation is Most Used Virtual Simulations for UG Nursing Programs 4. GLOBAL MARKET PERSPECTIVE III. MARKET ANALYSIS IV. COMPETITION For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

DUBLIN--( BUSINESS WIRE )--The "Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023" report has been added to ResearchAndMarkets.com's offering. The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies. This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2016. There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments. Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal. Another reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project. The report provides a detailed understanding and analysis of how and why companies enter joint venture deals. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of all joint venture deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of joint venture dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in joint venture as well as a discussion on the merits of the type of deal. Chapter 3 provides an overview of the structure of joint venture deals. The chapter includes numerous case studies to enable understanding of joint venture deals. Chapter 4 provides a review of the leading Joint venture deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database. Chapter 5 provides a comprehensive listing of the top 25 most active Joint venture dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. Chapter 6 provides a comprehensive and detailed review of Joint venture deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the Joint venture deal. The appendices to the report includes a comprehensive listing of all Joint venture deals announced since 2016. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document. The report also includes numerous table and figures that illustrate the trends and activities in Joint venture dealmaking since 2016. In conclusion, this report provides everything a prospective dealmaker needs to know about Joint venture alliances. Key benefits Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 provides the reader with the following key benefits: In-depth understanding of joint venture partnering deal trends since 2016, with real life case studies Comprehensive listing of all joint venture deals since 2016, together with deal terms, value and press release Comprehensive access to actual joint venture contracts entered into by the world's life science companies Insight into the terms included in a joint venture agreement, together with real world clause examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Report scope Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 is intended to provide the reader with an in-depth understanding of the joint venture trends and structure of deals entered into by leading life science companies worldwide. Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 includes: Trends in joint venture dealmaking in the biopharma industry since 2016 Case studies of real-life joint venture deals Comprehensive listing of joint venture deals since 2016 Access to joint venture contract documents The leading joint venture deals by value since 2016 Most active joint venture dealmakers since 2016 The leading joint venture partnering resources In Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 available deals and contracts are listed by: Company A-Z Headline value Therapeutic area Technology type Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand. The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive access to available contract documents for joint venture deals. Companies Mentioned 3SBio 1717 Life Science Ventures A*STAR Agency for Science Technology and Research A*STAR Institute of Microelectronics (IME) A*STAR' Institute of Molecular and Cell Biology A2A Pharmaceuticals AAP Implantate AG Abbott Laboratories Abbvie Abilita Bio ABIVAX Abzena Accellix Accuray Acnos Pharma Adept Neuro Adisseo Advanced Prenatal Therapeutics Advanced Technologies Solutions Aequus Pharmaceuticals Agilis Biotherapeutics AgonOx AirWare Labs Aitbiotech Akers Biosciences AKESOgen Aleafia Health Aleva Neurotherapeutics Allied-Bristol Life Sciences Allied Minds Ally Bridge Group Altus Formulation Alzheimer's Association Alzheimer's Research UK Amarantus BioSciences Amendia American Diabetes Association AmerisourceBergen Amunix Amyris AnaBios Anokion Antitope Antoxerene Apax Partners Aphria Arbele Arbutus ARCH Personalized Medicine Initiative Aridis Pharmaceuticals Aruvant Sciences Arvinas Ascendance Biotechnology Ascendis Pharma Asklepios Biopharmaceutical Aslan Pharma Astellas Pharma AstraZeneca ATAI Life Sciences Athenex ATL Technology Atomwise Atrapos Therapeutics Atropos Therapeutics Auramedi Farmaceutica Autobio Diagnostics AUT Roche Diagnostics Laboratory AUT University Auxly Cannabis Group Avacta Avactis Biosciences Avalon GloboCare Avivagen Avvinity Therapeutics Axis Therapeutics Bain Capital Baxter International Bayer Baylor College of Medicine Baylor Miraca Genetics Laboratories B Braun B Braun CeGaT Beckley Canopy Therapeutics Beckley Foundation Becton Dickinson BeiGene Beijing Genomics Institute (BGI) Beijing Leadman Biochemistry Berry Genomics Betaliq BevCanna BGI Tech Solutions BHB Therapeutics Bill and Melinda Gates Foundation Bio-Techne BioAmber Biodist Biodyne USA BioFields Biogen Biohealth Innovation BioHeart BioLife Solutions BioLight BiolineRX biologistex CCM BioMed X Innovation Center Biomerics BioMotiv BioPharma Services Blackstone Blockshine Technology Bloomage BioTechnology Bloom Burton BLP Management Blueberries Medical Boehringer Ingelheim Breakthrough Diagnostics Brigham and Women's Hospital Bristol-Myers Squibb Broad Institute Buchang Pharmaceutical Buck Institute for Age Research Bukwang Pharmaceuticals Button Capital Calysta Energy Cancer Research Technology Cannabics Pharmaceuticals Cannabis Biocare Cannabis Therapeutics CannAmerica Brands CannaRoyalty Canopy Health Innovations Capna Intellectual Capnia Cardio3 Biosciences Asia Holdings Casebia Therapeutics Catapult Therapy TCR CB2 Therapeutics CBDerma Technology CBDistribution Cedar Gate Technologies CeGaT Cell Therapy Catapult Celyad Centauri Therapeutics Centene Center for Genetic Engineering and Biotechnology (Cuba) Centre for Commercialization of Regenerative Medicine (CCRM) Centro de Inmunolgia Molecular Cerevel Therapeutics Cesca Therapeutics Chan Soon-Shiong Institute of Molecular Medicine ChemAxon Children's Medical Research Institute Chimera Biotec China-Israel Biological Technology China-Singapore Guangzhou Knowledge City China Isotope And Radiation Chinese Academy of Science Chinese Future Industry Investment Fund Chongqing PSK-Health Sci-tech Development Cincinnati Children's Hospital Medical Center City of Hope CJ CheilJedang ClearPath Cloaked Therapeutics Co-Diagnostics Cohen Veterans Bioscience Cold Spring Harbor Colibri Heart Valve Collagen Solutions Plc Columbus Venture Partners Concentrics Research Consortium AI Corestone Biosciences Cornerstone Animal Health Corning Covenant Animal Health Partners Cre8ive CRISPR Therapeutics CureCell Cyclica CytoBioscience Cytotheryx Cytovant Sciences Daewoong Pharmaceutical Dance Biopharm Dasman Diabetes Institute David Snow Deerfield Management DemeRx Demetra Denka Denka-KEW Genomics DepYmed DIAN Diagnostics Diavax Biosciences Dixi Dizal Pharmaceutical DolCas-Tenshi Bioceuticals DolCas Biotech Dona Blanca Dongbao Dr. Walter Bell Duke-NUS Graduate Medical School Singapore Eastar Industries Eastern Capital Easton Pharmaceuticals eCardio Diagnostics Eddingpharm Eden BioCell Elanix Biotechnologies Elevar Therapeutics Eli Lilly EMD Millipore EMD Serono Emergence Therapeutics EmoCellix Emory University Emosis Enigma Diagnostics Enova Illumination Entheogenix Biosciences ERS Genomics Evotec ExCellThera Exemplar Genetics Facebook Faes Farma Faxian Therapeutics Fedecore Fedora Pharmaceuticals FerGene Ferring Pharmaceuticals FJ Pharma Flexpoint Ford Flow Pharma Fonterra Food and Drug Administration (FDA) FORMA Therapeutics Fortress Biotech Fosun Pharmaceutical FoxBio Fox Chase Cancer Center Fraunhofer Institute for Microelectronic Circuits and Systems Frazier Healthcare Ventures Fresenius Kabi Pharmaceuticals Frontage Laboratories FSD Pharma Futura Medical Fuzionaire Diagnostics Fuzionaire Radioisotope Technologies G-treeBNT Galectin Sciences Galectin Therapeutics Galvani Bioelectronics Gauss Surgical Genentech Gene Therapy Research Institution Genetic Technologies Genevant Sciences Genome Institute of Singapore Genomix Scientific Gentag GeoVax German Research Center for Artificial Intelligence Gerresheimer GHO Capital Ginkgo BioWorks GlaxoSmithKline For more information about this report visit https://www.researchandmarkets.com/r/laae8e About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

欢迎关注凯莱英药闻CAR-T 疗法，全称为Chimeric antigen receptor T cells，嵌合抗原受体T 细胞免疫疗法，是指经过基因工程改造过的，可以表达特定T 细胞受体，用于免疫治疗的一类T 细胞。CAR-T 中的嵌合抗体给予了改造后的T 细胞识别特定蛋白的能力，嵌合一词的解释是因为其抗体既具有抗原识别功能也具有T 细胞激活功能。CAR-T 细胞源既可以是 CD4+ 也可以是 CD8+，两种细胞类型的比例为 1:1，可提供协同抗肿瘤作用。CAR-T 细胞可以来源于患者自身血液中的 T 细胞（自体），也可以来源于另一个健康供体的 T 细胞（异体）。自体CAR-T 细胞是从患者血液中获取T 细胞，再通过带有对CAR 结构编码的质粒的病毒载体转染等方式，使得CAR-T细胞具有靶向目标细胞的能力，进而实现疾病治疗。自体CAR-T不是常规意义上的药品，而是一种个性化治疗技术，需要病人自身的T细胞在体外转导-扩增-回输，病人等待治疗的时间长达3星期。而同种异体CAR-T 细胞来源于同种异体来源或是从iPSC 来源的T 细胞，又被称为通用型CAR-T细胞，往往需要借助免疫抑制剂等手段联合治疗以克服免疫排斥等副作用。通用型CAR-T细胞与传统药品基本没有区别，其生产成本更低、可立即给药、使用/分发/存储方式与抗体药物类似。它能够降低成本，缩短患者等待时间，适用患者范围更广，不受治疗中心分布限制，因此能够解决自体CAR-T临床应用中的主要问题，有望成为更多患者的选择，是未来CAR-T的重要发展方向。在临床应用方面，目前CAR-T 疗法大多数的临床试验主要集中在血液瘤。CD19 仍然是最流行的抗原靶点，其次是 BCMA。相比于血液瘤，CAR-T 在实体瘤中的应用有限。原因包括：（1）因实体瘤的异质性，找到仅在癌细胞上高度表达的抗原具有相当的难度。（2）CAR-T 细胞不能有效地运输到实体瘤块的中心，而且肿瘤微环境会抑制 T 细胞活性。从全球范围来看，目前上市的产品均是针对CD19 和BCMA靶点，其中产品销售收入呈现出良好的增长趋势；随着两款CAR-T产品在国内的获批，特别是传奇生物BCMA CAR-T 获FDA 批准，国产免疫细胞治疗技术已迈上国际舞台。一最新研究进展1、市场预测：根据Frost & Sullivan 的数据，全球CAR-T 细胞治疗市场从2017 年的0.1亿美元增长到2019 年的7 亿美元和2020年的11 亿美元，预计未来几年将加速增长，2024 年将扩大至66 亿美元，2019年至2024 年复合年增长率预计为55.0%。预计2030 年市场将进一步增长至218亿美元，2024 年至2030 年复合年增长率预计为22.1%。2、靶点情况：据不完全统计，目前在研药物数量800余种，根据靶点的研究数量，依次是：CD19、BCMA、CD22、MSLN、CD20、PD1、EGFR、CLDN18.2、GPC3、GD2。3、企业情况：根据研究数据，国内公司表现抢眼，其中雅科生物布局CAR-T数量约27个、Celgene约21个、Novartis约15个、传奇生物14个、Avalon GloboCare 14个、凯地医疗13个；此外，布局CAR-T的国内企业还包括朗森生物、科济药业、波睿达生物、驯鹿医疗、博生吉、精准生物等。4、  II期及以上阶段药物研发情况：二重点企业及药物介绍1、复星凯特：阿基仑赛阿基仑赛（商品名奕凯达，英文商品名Yescarta，通用名简称Axi-Cel）是复星凯特引进美国Kite 公司全球第二个获批的CAR-T 产品Yescarta，获授权在中国进行本地化生产，于2021 年6 月23日首个获药监局批准上市的靶向CD19 的产品。阿基仑赛是通过慢病毒载体转导，包含胞外鼠源抗CD19 单抗、胞内CD3 ζ信号结构域及CD28 共刺激结构域的靶向CD19 的CAR-T产品。2022 年4 月，FDA 批准了Yescarta 用于一线化疗免疫疗法难治或一线化疗免疫疗法后12 个月内复发的大B 细胞淋巴瘤成年患者。此次批准是基于的ZUMA-7 研究结果，这项大型随机、全球多中心的III 期研究，共有359 个患者纳入分析，在无事件生存期（EFS）、客观应答率（ORR）、总生存期（OS）及无进展生存期（PFS）等指标上，单次注射的CAR-T 药物显著优于传统的标准疗法（Standard of Care）。自此，临床优先级提高到一类推荐，是CAR-T 疗法发展过程中的一次里程碑。2、传奇生物：西达基奥仑赛西达基奥仑赛（英文商品名CARVYKTI ，通用名简称Cilta-cel，研发代号JNJ-4528）是全球范围内继idecabtagene vicleucel （Abecma ）后第二款上市的靶向BCMA的CAR-T 药物，2022 年2 月获得FDA 批准上市，用于复发性或难治性多发性骨髓瘤，也是首款在美国上市的国产CAR-T药物。西达基奥仑赛由慢病毒载体转导，CAR 包含两种来源的单域抗体（sdAbs）、胞内CD3 ζ信号结构域及4-1BB共刺激结构域。2021 年12 月，强生与传奇生物在ASH 更新了Ib/II 期临床研究CARTITUDE-1的数据，在中位随访18 个月过程中，97 名受试者整体ORR达到97.9%，其中80.4%的患者实现了完全缓解（sCR）（注：2022 年2 月28 日FDA 更新的sCR 数据为78.4%）。18 个月PFS 和OS 分别为66.0%和80.9%。中位CRS 发生时间是7 天，大部分程度较轻。在FDA 上市监管书里所展示的ORR，sCR等有效性数据来看，CARVYKTI 相较于Abecma的优势更明显。3、科济药业：CT041、CT053CT041是全球潜在同类首创Claudin18.2 CAR-T，目前处于II期临床阶段，正在开发用于治疗胃癌、胃食管交界处癌、胰腺癌。根据最新的研究数据，在一项单臂、开放标签的1b期试验在美国6个中心，针对之前接受过至少两种前线系统治疗的胃癌/食管胃结合部腺癌（GC/GEJ）患者以及至少接受过一种前线治疗的胰腺癌患者开展的试验中，显示已有14例患者入组（5例患有胃癌/食管胃结合部腺癌，9例患有胰腺癌），既往中位治疗线数为3线（范围1-5），且共接受了18个周期的CT041治疗。结果显示，在胃癌/食管胃结合部腺癌患者的分组中， ORR为60%，其中1例患者实现了CR；此外，在80%（4/5）的疾病稳定（4例胰腺癌患者）患者中观察到了肿瘤的缩小；中位缓解持续时间（mDOR）和中位无进展生存期（mPFS）尚未达到；接受DL3的两例患者在数据截止日期前尚未进行肿瘤疗效评估。在DL1和DL2中观察到剂量依赖性反应，其中在DL1中观察到的ORR为16.7%，疾病控制率（DCR）为50%；在DL2中观察到的ORR为33.3%，DCR为83.3%。CT053是全人BCMA CAR-T，目前处于II期临床阶段，正在开发用于多发性骨髓瘤。根据在美国血液学会（ASH）年会上公布的数据，其中包括了（1）一项在中国开展的Ⅰ/Ⅱ期研究（LUMMICAR-1）的持续有效性和安全性结果，和（2）在复发/难治多发性骨髓瘤（R/R MM）受试者中的高危因素汇总分析。结果显示：（1）截至2021年7月8日，14位既往经多种治疗的R/R MM患者接受了CT053输注。3名患者接受了1.0×108 CAR-T细胞；11名患者接受了1.5×108 CAR-T细胞。所有的患者都接受过至少三种前线治疗方案，前线治疗方案的中位数为6。其中，50%（7/14）的患者具有高危细胞遗传学异常，14.3%（2/14）的患者伴有髓外病变（EMD），以及14.3%（2/14）的患者伴有国际分期系统（ISS）III期。在安全性上，总体耐受性良好，无≥3级细胞因子释放综合征（CRS）和神经毒性发生，无剂量限制性毒性（DLT）和治疗相关死亡事件发生。未检测到药物免疫原性（2）在中位随访13.9个月中，ORR为92.1%（35/38），其中78.9%（30/38）的患者达到CR/sCR，86.8%（33/38）的患者达到VGPR及以上。mPFS和mDOR分别为22.7个月和24.0个月。在安全性上，无DLT或者治疗相关死亡事件发生。1级或2级的CRS发生率为73.7%，且没有≥3级的CRS发生。仅1例（2.6%， 1/38）患者发生3级神经毒性（癫痫），且经甲泼尼龙治疗后完全恢复，该患者ISS III期，合并EMD。4、Precision BioSciences：PBCAR0191PBCAR0191是Precision BioSciences研发的首款异体CAR-T产品，利用ARCUS技术敲除异体CAR-T细胞中编码TCR的基因，以避免移植物抗宿主病，同时利用AAV转入靶向CD19的CAR，插入ARCUS编辑位点，用于杀伤CD19+的肿瘤细胞。目前，处于临床I期阶段，正在开发用于非霍奇金淋巴瘤和B细胞急性淋巴细胞白血病。2022年6月，Precision BioSciences公布了PBCAR0191最新的临床试验结果。对两个队列的分析结果显示，截至2022年5月31日，共有11名CD19 CAR-T复发B-NHL患者可进行评估，第28天ORR达到100%（11/11），其中8例（73%）患者达到CR，6名可评估的患者中3例（ 50% ）患者DoR超过6个月，11例患者中仍有6例（55%）持续响应。一例达到CR的患者维持时间已超过18个月。在New Cohort的5例可评估患者中，ORR为100%，CR为100%，一例患者死亡，其余4例仍维持CR状态。5、Adicet Bio：ADI-001ADI-001是由Adicet Bio开发的一款靶向CD20的同种异体CAR-γδ T细胞，其细胞来源并不是一般CAR-T疗法较多采用的αβ T细胞，而是占T淋巴细胞的0.5%-5%的γδT细胞，目前正在开发用于治疗非霍奇金淋巴瘤。ADI-001表面的T细胞受体(TCR)由γ链和δ链组成，不需要与主要组织相容性复合物(MHC)分子结合，并且不需要通过抗原提呈细胞(APC)，因此通常认为其不具有移植物抗宿主反应（GVHD），免疫原性较低。根据ASCO公布的数据，28天治疗后，ORR为67%，且所有ORR患者均转化为CR（67%），整体治疗效果优异。78%的副作用为1-2级，33%的CRS率（1-2级），安全性表现良好。6、精准生物：MC-1-50MC-1-50是由精准生物开发的新一代CAR-T，目前正在开发用于B细胞急性淋巴细胞白血病、滤泡性淋巴瘤、套细胞淋巴瘤、弥漫性大B细胞淋巴瘤。MC-1-50是基于基于快速CAR-T 生产平台PrimeCAR开发，可以在48小时内产生CAR-T细胞，并配合严密的质控体系，能够实现患者7天内完成细胞输注，减少患者等待时间，同时极大提高生产效率、降低生产成本。根据ASCO公布的数据，截至2022年2月10日，有13例r/r B-ALL患者接受了MC-1-50治疗，入组患者的平均骨髓瘤荷达到58.4%，治疗过程中未发现剂量限制性毒性。84%的患者发生了CRS，其中1级CRS 7例(54%)，2级CRS 4例(30%)，未观察到≥3的CRS。一例患者(7%)发生1级ICANS，未发生≥2级ICANS。7、亘喜生物：GC012FGC012F是由亘喜生物开发的新一代CAR-T，利用独有的FasTCAR技术，具备“次日完成生产”优势，目前正在开发用于多发性骨髓瘤。根据ASCO公布的数据，入组28例患者分别接受了GC012F三种剂量水平的单次输注治疗。在所有可进行微小残留病灶（MRD）疗效评估的患者中，100%（27/27）的患者达到了MRD阴性；75%（21/28）的患者达到了微小残留病灶阴性-严格意义上的完全缓解（MRD- sCR）。聚焦药靶系列文章1.  国内CAR-T疗法最新研究进展2.  “老药新用”治疗NASH的临床进展3.  未来可期的PROTAC：全球最新研发进展4.  PROTAC之后：期待溶酶体降解技术的突破5.  双星闪耀，PROTAC光环下的分子胶最新研究进展6.  从罕见病到新冠治疗，补体药物的研发之路7.  靶向GABA受体的药物研发进展8.  200亿美元市场，S1PR调节剂还有哪些新进展9.  FGFRs，下一个不限癌种的新靶标？10. 双特异性抗体的发展现状及趋势11. 巨头竞赛、受中国公司青睐的c-Met，会打开什么样的格局？12. 面对新冠病毒，mRNA疫苗会是未来的希望吗？13. 打破“不可成药”魔咒，SHP2抑制剂谁将率先突围？14. 最热胃癌靶点CLDN18.2的研究进展15. TIGIT，能复制PD-1/CTLA-4的奇迹吗？16. STING——使肿瘤由“冷”转“热”的免疫治疗靶点17. 挑战恶性血癌，靶向FLT3药物的最新进展18. TCR-T，治疗实体瘤的新曙光19. BTK抑制剂市场谁领风骚？2026年市场规模或接近200亿美元20. 靶向RET抑制剂突飞猛进，“小众”突变走入大众视野21. 胃肠道肿瘤的克星，KIT抑制剂的最新研究进展22. PCSK9抑制剂，降脂领域的新星23. HDAC抑制剂的最新研究进展24. CD73，成为攻克实体瘤的新希望25. PARP抑制剂，不可不知的肿瘤靶向药26. 老靶点HER2研发热度只增不减，新药层出不穷27. P53的新药开发即将迎来破冰时刻？28. 一文尽览肿瘤免疫治疗分子CTLA-4的研究现状29. PD-1 / PD-L1，内卷何时休？30. LAG-3，肿瘤免疫治疗的又一场豪赌31. 小分子药的春天，PROTAC的最新研究进展32. 穿胶水的“恶魔”，靶向蛋白降解剂中分子胶的最新进展33. 比PROTAC应用更广泛的溶酶体降解技术的发展和挑战34. Tacs又出新概念？一览靶向嵌合体技术发展的新趋势35. “踩油门”靶点4-1BB的最新研究进展36. 从抗炎到细胞治疗，针对克罗恩病的最新研发进展37. 从诊断到治疗，PSMA的最新研究进展38. 实体瘤“明星靶点”MSLN的最新研究进展39. 肝细胞癌治疗的新曙光，GPC3的最新研究进展40. 热门免疫检查点TIM3的最新研究进展41. TNF-α抑制剂江湖大战，谁主沉浮？42. 赛道竞争激烈，RSV药物谁能脱颖而出？43. 顶级药企斥巨资入局，RIPK1靶点如何成为潜力股？44. 广泛分布人体的神经紧张素受体或成新兴靶点？一起来看NTS及NTSR的最新研究进展45. AbTac、GlueTac、AutoTac等新技术持续赋能，一起来看Tac的最新研究进展46. 1+1＞2，双特异性抗体的最新研究进展47. “合成致死”迎来转机，一起来看PRMT5抑制剂的最新研究进展48. 多家国内药企青睐，CCR8未来可期49. 有望克服自身缺陷，Menin大有可为50. 抗癌更要抗炎，IRAK4的最新研究进展51. “以毒攻毒”——溶瘤病毒的最新研究进展52. 迭代中的JAK抑制剂，谁能在大战中突出重围？53. KRAS大战一触即发，谁能笑到最后？54. 新药发展第三次浪潮——小核酸药物的最新研究进展55. PROTAC研发掀热潮，创新转型正当时感谢关注、转发，转载授权、加行业交流群，请加管理员微信号“hxsjjf1618"。参考资料1、各公司官网2、中银国际、华创证券、兴业证券、民生证券